A systematic review of the effectiveness of adalimumab
A systematic review of the effectiveness of adalimumab
A systematic review of the effectiveness of adalimumab
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
TABLE 135 Variation 11: TNF inhibitors third (early RA values) (100,000 patients) (cont’d)<br />
© Queen’s Printer and Controller <strong>of</strong> HMSO 2006. All rights reserved.<br />
Health Technology Assessment 2006; Vol. 10: No. 42<br />
Et+M – Ad+M 11,436 117 0.4486 0.0152<br />
In+M – Ad+M 78 96 –0.0229 0.0145<br />
Et+M – In+M 11,357 116 0.4715 0.0152<br />
Comparison ICER (£ per QALY) Quasi-CI<br />
Adal – Base 36,700 35,100 to 38,600<br />
Etan – Base 32,000 31,100 to 32,900<br />
Ad+M – Base 32,200 30,900 to 33,600<br />
Et+M – Base 29,600 28,800 to 30,400<br />
In+M – Base 33,400 32,000 to 34,900<br />
Ad+M – Adal Adal+MTX more effective than Adal alone; diff. cost not significant<br />
Et+M – Etan Etan+MTX more effective than Etan alone; diff. cost not significant<br />
Etan – Adal 25,500 23,800 to 27,500<br />
Et+M – Ad+M 25,500 23,800 to 27,400<br />
In+M – Ad+M Comparison is inconclusive<br />
Et+M – In+M 24,100 22,600 to 25,800<br />
TABLE 136 Variation 11: TNF inhibitors third (late RA values) (200,000 patients)<br />
Option Cost (£) QSE QALYs QSE<br />
Adal 38,431 52 5.5641 0.0101<br />
Etan 49,697 70 6.0961 0.0106<br />
Adal+MTX 38,502 52 5.7344 0.0101<br />
Etan+MTX 49,806 70 6.0959 0.0106<br />
Infl+MTX 38,541 50 5.5583 0.0101<br />
Base 16,490 16 5.3809 0.0097<br />
Comparison Diff. cost (£) QSE Diff. QALY QSE<br />
Adal – Base 21,940 51 0.1832 0.0099<br />
Etan – Base 33,207 69 0.7153 0.0103<br />
Ad+M – Base 22,012 51 0.3536 0.0099<br />
Et+M – Base 33,316 69 0.7150 0.0103<br />
In+M – Base 22,050 49 0.1774 0.0099<br />
Ad+M – Adal 72 69 0.1704 0.0099<br />
Et+M – Etan 109 93 –0.0003 0.0107<br />
Etan – Adal 11,266 82 0.5321 0.0102<br />
Et+M – Ad+M 11,304 82 0.3614 0.0104<br />
In+M – Ad+M 38 68 –0.1762 0.0099<br />
Et+M – In+M 11,265 81 0.5376 0.0104<br />
Comparison ICER (£ per QALY) Quasi-CI<br />
Adal – Base 120,000 108,000 to 134,000<br />
Etan – Base 46,400 45,100 to 47,800<br />
Ad+M – Base 62,300 58,900 to 66,000<br />
Et+M – Base 46,600 45,300 to 48,000<br />
In+M – Base 124,000 112,000 to 140,000<br />
Ad+M – Adal Adal+MTX more effective than Adal alone; diff. cost not significant<br />
Et+M – Etan Comparison is inconclusive<br />
Etan – Adal 21,200 20,300 to 22,100<br />
Et+M – Ad+M 31,300 29,500 to 33,200<br />
In+M – Ad+M Adal+MTX more effective than Infl+MTX; diff. cost not significant<br />
Et+M – In+M 21,000 20,100 to 21,900<br />
207
Change language